@FierceMedDev: ICYMI: Siemens sells hearing aid biz for $2.7B amid rumors it will exit healthcare entirely. Story | Follow @FierceMedDev
@VarunSaxena2: UPDATE: The new AstraZeneca, University of Manchester center for drug delivery becomes operational in February. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: Google signs onto Foundation Medicine cancer Dx by offering tests to employees. FierceDiagnostics article | Follow @EmilyWFierce
> CareFusion ($CFN) reported FY 2015 Q1 earnings of $76 million on earnings of $922 million. Earnings rose 8% and revenue increased 11%. Release
> Volcano ($VOLC) reported Q3 revenues of $97.5 million compared to $95.8 million in Q3 2013. The quarterly net loss fell to $8 million from $8.5 million. Release
Biotech News
@FierceBiotech: Intercept shares slide as investigators question OCA's safety/efficacy for NASH. Article | Follow @FierceBiotech
@JohnCFierce: That's a big no to $NVS--FDA advisers spurn Novartis' blood cancer drug, putting approval in doubt. Report | Follow @JohnCFierce
@DamianFierce: A biotech developing a concussion treatment has recruited Brett Favre to help it raise money for R&D, because hey. Release | Follow @DamianFierce
> Avanir's odds for a timely drug approval aren't looking so good. Story
> INC banks $150M in the latest big CRO IPO. Report
> Rockwell clears an FDA hurdle with its dialysis drug. Article
Pharma News
@FiercePharma: Top-read pharma news Thurs--New numbers back old meme: Pharma does spend more on marketing than R&D. Article | Follow @FiercePharma
@EricPFierce: FDA punishes Ranbaxy for plant problems. Snatches away its approval for generic Nexium. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI earlier: This week's full issue of FierceVaccines. Subscribe here. | Follow @CarlyHFierce
> UCB joins pharma's slimdown craze, unloads U.S. generic drug business for $1.53B. More
> Fresenius kills Russian partnership as political tensions escalate. Article